Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15940842 | 0.81 | ENPP2 (0.50) | LPLLIPGENPP2 | |
| SCHEMBL3865554 | 0.80 | LPL (0.33) | LPLLIPGENPP2CA1CA2 | |
| Hydrochloric Acid SCHEMBL29955592 | 0.79 | ENPP2 (0.48) | LPLLIPGENPP2 | |
| SCHEMBL2216611 | 0.79 | SMYD3 (0.32) | LPLLIPGSMYD3MAPTHTT | |
| SCHEMBL2067301 | 0.79 | CYP11B2 (0.42) | LPLLIPGENPP2CA1CA2 | |
| SCHEMBL17847176 | 0.79 | GABRA1 (0.34) | LPLLIPGENPP2 | |
| SCHEMBL17997487 | 0.79 | DYRK1A (0.36) | LPLLIPGENPP2MAPT | |
| SCHEMBL17556274 | 0.79 | CHRNB2 (0.43) | LPLLIPGENPP2MAPTCHRNB2 | |
| SCHEMBL10311181 | 0.78 | LIPG (0.59) | LPLLIPGCA1CA2TRPV1 | |
| SCHEMBL240843 | 0.77 | SMYD3 (0.39) | SMYD3MAPTHTTSMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11932657-B2 | Heterocyclic compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210340157-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-11-04 | — | — | US | disclosed |
| EP-3847176-A1 | HETEROCYCLIC COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112654627-A | Heterocyclic compounds | 大塚制药株式会社 | 2021-04-13 | — | — | CN | disclosed |
| WO-2019156989-A1 | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR | IDEAYA BIOSCIENCES, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| EP-3056207-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | US | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088160-A2 | NOVEL CYP17 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172814-B2 | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | PTGER1, PTGES, PTGES3 | LPL 2809/4885LIPG 1050/4885ENPP2 37/4885 |
| US-20110178065-A1 | NOVEL CYP17 INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | LPL 654/4885LIPG 539/4885ENPP2 2457/4885 |
| US-20170354620-A1 | SUBSTITUTED PYRIDYL-CYCLOALKYL-CARBOXYLIC ACIDS, COMPOSITIONS CONTAINING THEM AND MEDICAL USES THEREOF | PTGER1, PTGES, PTGES3 | LPL 2809/4885LIPG 1050/4885ENPP2 37/4885 |
| US-20210340157-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | LPL 1612/4885LIPG 963/4885ENPP2 871/4885 |
| US-11932657-B2 | Heterocyclic compound | AHR, PDGFRA, PDGFRB | LPL 1612/4885LIPG 963/4885ENPP2 871/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | LPL 1612/4885LIPG 963/4885ENPP2 871/4885 |
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | LPL 1369/4885LIPG 782/4885ENPP2 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.